Shan Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shan Gao has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
Pan Cheng
Department of Pharmacology, Basic Medical College, Anhui Medical University, Hefei, 230032, China
6 shared publicationsYan-Mei Xu
School of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China
5 shared publicationsZhen Wang
Department of Pharmacology School of Pharmacy Anhui Medical University Hefei China
5 shared publications- Ai-Zong Shen
Department of Pharmacy, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China
4 shared publications Cheng Xu
School of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China
4 shared publicationsJuan Hu
Department of Pharmacology, Basic Medical College, Anhui Medical University, Hefei, Anhui 230032, P.R. China
4 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (9) , 117973
Integrated stress response inhibition decouples cardiotoxicity from anthracycline chemotherapy while enhancing antitumor efficacy
- 9 September 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (9) , 117973
Open AccessIntegrated stress response inhibition decouples cardiotoxicity from anthracycline chemotherapy while enhancing antitumor efficacy
- 3 June 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (52)
Single‐Dose Injectable Microalgae Hydrogel for Sustained and Targeted Drug Delivery in Early Myocardial Ischemia/Reperfusion Injury Therapy
Single‐dose therapy represents a promising strategy to enhance the convenience and patient compliance in treating myocardial ischemia/reperfusion (MI/R) injury, a long‐lasting therapeutic bottleneck in ischemic heart disease. Nevertheless, existing single‐dose strategies fail to simultaneously address key pathological challenges, including reperfusion‐induced oxidative stress, myocardial hypoxia, and poor drug targeting. Herein, we develop an injectable calcium alginate microgel (termed CaALG‐IMTP@NBP), which is co‐loaded with oxygen‐producing microalgae/perfluorotributylamine (PFTBA) emulsion and DL‐3‐ n ‐butylphthalide (NBP), and is functionalized with an ischemic myocardium‐targeting peptide (IMTP). This composite offers three synergistic benefits: PFTBA oxygen storage enables light‐independent, sustained oxygen release (∼6.5 mg/L); IMTP modification facilitates precise binding to exposed cTnI, extending cardiac drug retention to 3 h and increasing local NBP concentration by 2.1‐fold; and the CaALG matrix provides pH‐responsive, sustained release of loaded NBP, which activates the Nrf2/HO‐1 pathway to suppress oxidative stress and reduce cardiomyocyte apoptosis by 57%. In a mouse MI/R model, a single pre‐ischemic injection of CaALG‐IMTP@NBP significantly improved cardiac function (32% increase in LVEF), reduced infarct size by 45%, and lowered serum biomarkers, outperforming daily oral NBP. This biocompatible and biodegradable platform establishes a novel strategy for single‐dose MI/R therapy and holds immense potential for clinical translation.
- 3 June 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (52)
Single‐Dose Injectable Microalgae Hydrogel for Sustained and Targeted Drug Delivery in Early Myocardial Ischemia/Reperfusion Injury Therapy
Single‐dose therapy represents a promising strategy to enhance the convenience and patient compliance in treating myocardial ischemia/reperfusion (MI/R) injury, a long‐lasting therapeutic bottleneck in ischemic heart disease. Nevertheless, existing single‐dose strategies fail to simultaneously address key pathological challenges, including reperfusion‐induced oxidative stress, myocardial hypoxia, and poor drug targeting. Herein, we develop an injectable calcium alginate microgel (termed CaALG‐IMTP@NBP), which is co‐loaded with oxygen‐producing microalgae/perfluorotributylamine (PFTBA) emulsion and DL‐3‐ n ‐butylphthalide (NBP), and is functionalized with an ischemic myocardium‐targeting peptide (IMTP). This composite offers three synergistic benefits: PFTBA oxygen storage enables light‐independent, sustained oxygen release (∼6.5 mg/L); IMTP modification facilitates precise binding to exposed cTnI, extending cardiac drug retention to 3 h and increasing local NBP concentration by 2.1‐fold; and the CaALG matrix provides pH‐responsive, sustained release of loaded NBP, which activates the Nrf2/HO‐1 pathway to suppress oxidative stress and reduce cardiomyocyte apoptosis by 57%. In a mouse MI/R model, a single pre‐ischemic injection of CaALG‐IMTP@NBP significantly improved cardiac function (32% increase in LVEF), reduced infarct size by 45%, and lowered serum biomarkers, outperforming daily oral NBP. This biocompatible and biodegradable platform establishes a novel strategy for single‐dose MI/R therapy and holds immense potential for clinical translation.
- 10 January 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 360, 121194
Xin-Ji-Er-Kang improves MIR injury–induced heart failure via the Calpain1/Bid signaling pathway
- 10 January 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 360, 121194
Xin-Ji-Er-Kang improves MIR injury–induced heart failure via the Calpain1/Bid signaling pathway
- 7 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 151, 157800
Xin-Ji-Er-Kang alleviates heart failure induced by myocardial ischemia-reperfusion injury through reshaping gut microbiota and metabolites
- 7 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 151, 157800
Xin-Ji-Er-Kang alleviates heart failure induced by myocardial ischemia-reperfusion injury through reshaping gut microbiota and metabolites
- 14 December 2025
- Published by Elsevier in Phytomedicine
- Vol. 150, 157714
Xin-Ji-Er-Kang alleviates chronic heart failure by suppressing mtDNA/cGAS-STING signaling through NR3C1-mediated MFN2 upregulation
- 14 December 2025
- Published by Elsevier in Phytomedicine
- Vol. 150, 157714
Xin-Ji-Er-Kang alleviates chronic heart failure by suppressing mtDNA/cGAS-STING signaling through NR3C1-mediated MFN2 upregulation
- Open Access
- 30 October 2025
- Published by Elsevier in Redox Biology
- Vol. 88, 103905
Integrated stress response-mediated metabolic reprogramming drives hepatic stellate cell activation and liver fibrosis via the noncanonical EIF3d-ATF4-S100P signaling pathway
- 30 October 2025
- Published by Elsevier in Redox Biology
- Vol. 88, 103905
Open AccessIntegrated stress response-mediated metabolic reprogramming drives hepatic stellate cell activation and liver fibrosis via the noncanonical EIF3d-ATF4-S100P signaling pathway